Chemotherapy for advanced prostate cancer

被引：0

作者：

Nabhan, C ^{[1
]}

机构：

[1] Oncol Specialists, Park Ridge, IL 60068 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 352卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：200 / 201

页数：2

共 5 条

[1]

DRESDEN SM, 2001, P AN M AM SOC CLIN, V20, pB168

[2] Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases [J].

Koutsilieris, M ;

Mitsiades, CS ;

Bogdanos, J ;

Dimopoulos, T ;

Karamanolakis, D ;

Milathianakis, C ;

Tsintavis, A .

CLINICAL CANCER RESEARCH, 2004, 10 (13) :4398-4405

[3] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

[4] Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients [J].

Saika, T ;

Kusaka, N ;

Tsushima, T ;

Yamato, T ;

Ohashi, T ;

Suyama, B ;

Arata, R ;

Nasu, Y ;

Kumon, H .

INTERNATIONAL JOURNAL OF UROLOGY, 2001, 8 (06) :290-294

[5] Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer [J].

Weitzman, AL ;

Shelton, G ;

Zuech, N ;

Owen, CE ;

Judge, T ;

Benson, M ;

Sawczuk, I ;

Katz, A ;

Olsson, CA ;

Bagiella, E ;

Pfaff, C ;

Newhouse, JH ;

Petrylak, DP .

JOURNAL OF UROLOGY, 2000, 163 (03) :834-837

← 1 →